Help protect yourself this season

Updated Novavax COVID-19 vaccine (2024-2025 Formula) now available.

woman standing with arms crossed
Who we are

Novavax is driving value using our validated recombinant nanoparticle and Matrix-M™ technology.

scientist looking into microscope
2024 Q3 earnings report

Novavax reports its 3rd quarter earnings and organizational highlights.

Committed to creating vaccines to help protect health

Novavax is a global biotechnology company with a proven vaccine technology. We’re focused on developing our R&D assets and establishing partnerships to leverage the value of our technology to help protect health. With a strong scientific foundation, our technology includes both our recombinant protein-based nanoparticle and Matrix-M™ adjuvant.

Our goal is to exponentially increase the impact of our technology in areas of unmet need. We are focused on doing this through:

Executing current partnerships

orange antigens image

Developing our late-stage assets

Driving additional partnerships and deals for our technology

Building a robust early-stage pipeline

Investor Hub

Visit our Investor Hub to access investor resources and information on upcoming and past events. Sign up to receive notifications for investor updates, such as upcoming events and webcasts, daily closing stock price, SEC filings, and press releases.

Learn more

View our pipeline